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Abstract
Background: Vaccination strategies that elicit antigen-specific tolerance are needed as therapies for autoimmune
disease. This study focused on whether cytokine-neuroantigen (NAg) fusion proteins could inhibit disease in
chronic murine models of experimental autoimmune encephalomyelitis (EAE) and thus serve as potential
therapeutic modalities for multiple sclerosis.
Results: A fusion protein comprised of murine GM-CSF as the N-terminal domain and the encephalitogenic
MOG35-55 peptide as the C-terminal domain was tested as a tolerogenic, therapeutic vaccine (TTV) in the C57BL/6
model of EAE. Administration of GMCSF-MOG before active induction of EAE, or alternatively, at the onset of EAE
blocked the development and progression of EAE. Covalent linkage of the GM-CSF and MOG35-55 domains was
required for tolerogenic activity. Likewise, a TTV comprised of GM-CSF and PLP139-151 was a tolerogen in the SJL
model of EAE.
Conclusion: These data indicated that fusion proteins containing GM-CSF coupled to myelin auto-antigens elicit
tolerance rather than immunity.
Background
In most patients, multiple sclerosis (MS) initially pre-
sents as a relapsing-remitting disease course that is
marked by periodic, self-limiting attacks interspersed
among prolonged periods of apparent clinical latency
[1-5]. Although the etiology of MS is not understood, a
prevalent theory is that molecular mimicry drives the
encephalitogenic attack [6-8]. Molecular mimicry may
be mediated by chronic infectious agents such as viruses
that exhibit prolonged latency but periodically reactivate
and consequently re-stimulate cross-reactive immunity.
With each reactivation, these chronic infectious agents
may elicit a new wave of effector and memory T cells
with cross-reactive specificity for viral epitopes and self
epitopes of CNS myelin. Focal infiltration of cross-reac-
tive T cells into the CNS is coupled with T cell-reactiva-
tion upon recognition of the cross-reactive self-myelin
antigens [9,10]. This process in turn drives inflammatory
demyelination and neurologic dysfunction. These
inflammatory processes are then postulated to elicit
negative feedback pathways and compensatory regula-
tory responses that enable spontaneous remission and
recovery. In many patients, this relapsing-remitting form
of MS evolves into a chronic progressive disease in
which periodic attacks are subsumed by an insidious
and continuous deterioration of neurological function
[11-14]. This transition from an inflammatory relapsing-
remitting disease to a progressive neurodegenerative
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spreading and erosion of regulatory T cell control. This
transition is also marked by a progressive loss in thera-
peutic efficacy of anti-inflammatory drugs.
EAE is a widely studied animal model of MS [5].
Some models of EAE are characterized by an acute
monophasic attack followed by a spontaneous remission
and permanent recovery whereas other EAE models
exhibit continual relapsing-remitting or chronic progres-
sive courses of disease. Monophasic, self-limiting models
of EAE that feature spontaneous, enduring recovery may
have more robust regulatory T cell responses compared
to those operative in chronic models. Likewise, strategies
of antigen-specific tolerance induction may be more
successful in monophasic models due to the potential
presence of more robust regulatory responses compared
to chronic models of EAE.
Cytokine- NAg fusion proteins have been studied in
the acute monophasic model of EAE in Lewis rats as
potent NAg-specific tolerogens [15-18]. Cytokine-NAg
fusion proteins were comprised of IL-2, IL-16, IFN-
beta, or GM-CSF as the cytokine domain and the
dominant encephalitogenic epitope of myelin basic
protein as the NAg domain. When administered before
encephalitogenic challenge, these TTV effectively pre-
vented the subsequent induction of EAE. When admi-
nistered during the onset of clinical signs, the same
TTV inhibited disease progression and accelerated
remission. Of these TTV, GMCSF-NAg was the most
efficient for targeting NAg to rat myeloid APC [15].
An important question is whether TTV-based strate-
gies of tolerance induction are effective in both mono-
phasic and chronic models of EAE, particularly across
both rat and mouse species.
In this study, a fusion protein comprised of murine
GM-CSF as the N-terminal domain and the encephalito-
genic MOG35-55 peptide as the C-terminal domain was
tested as a TTV in the C57BL/6 model of EAE. Subcu-
taneous administration of GMCSF-MOG in saline on
days -21, -14, and -7 inhibited the subsequent induction
of active EAE. A parallel GMCSF-PLP(139-151) fusion
protein was tolerogenic in the SJL model of EAE. Sev-
eral additional experiments focused on the GMCSF-
MOG TTV. When administration was initiated at the
onset of clinical signs in actively-immunized mice,
GMCSF-MOG prevented the progression of EAE. Cova-
lent linkage of the cytokine and MOG35-55 domains
was required for tolerogenic activity. When administered
during the course of passively-induced EAE, GMCSF-
MOG accelerated recovery and blunted a subsequent
active induction of EAE. In conclusion, GMCSF-NAg
TTV ameliorated disease in two chronic models of mur-
ine EAE. These data support the overall concept that
GMCSF-NAg fusion proteins are potent tolerogens in
both rat and mouse species and are effective in both
monophasic and chronic models of EAE.
Results
In vitro activities of GMCSF-MOG
The main question addressed in this study was whether
murine GMCSF-NAg TTV could block disease in mur-
ine models of chronic EAE, including the chronic pro-
gressive model of EAE in C57BL/6 mice and the
relapsing-remitting model of EAE in SJL mice. Murine
fusion proteins were derived which consisted of the
murine GM-CSF as the N-terminal domain and either
the MOG35-55 epitope or the PLP139-151 epitope as
the C-terminal domain. We first tested whether the
bioactivity of GM-CSF was altered by the C-terminal
addition of the NAg domain. The bioassays were based
on the use of C57BL/6 bone marrow cells (Figure 1A)
and the FDC-P1 cell line (Figure 1B). These assays
revealed that the GM-CSF activity of GMCSF-MOG and
GMCSF-PLP was essentially equipotent with murine
GM-CSF and rat GM-CSF. Independently-derived pre-
parations of each fusion protein were tested to verify
reliability of the fusion protein preparations. Sample to
sample variation of protein preparations was minimal.
The conclusion was that neither the MOG35-55 nor an
alternative PLP139-151 C-terminus interfered with the
activity of the GM-CSF domain. These and other experi-
ments revealed that mouse and rat GM-CSF proteins
were equally cross-reactive on both mouse and rat indi-
cator cells (data not shown).
Previous studies also showed that rat GMCSF-NAg
TTV were potent antigens in vitro [15]. The enhanced
antigenic potency of GMCSF-NAg TTV was due to high
affinity interactions of the cytokine domain with the
respective cytokine receptors on APC which targeted
the tethered NAg to the APC surface for enhanced pre-
sentation of NAg. As shown in Figure 2A, the rat
GMCSF-NAg TTV was approximately 1000-fold more
potent than the guinea pig (GP) myelin basic protein
(MBP) GP69-88 peptide when cultured with splenic
APC and the RsL.11 T cell clone or the rat 1B3 or 1E2
T cell hybrids. The murine GMCSF-MOG protein also
potently enhanced the recognition of the covalently
tethered MOG35-55 peptide when assayed in the pre-
sence of rat splenic APC and a rat T cell line specific
for MOG35-55 (Figure 2B). GMCSF-MOG was at least
1000-fold more potent as an antigen compared to
MOG35-55 and 10,000 fold more potent than the extra-
cellular IgV domain of rat MOG which contains the ver-
batim MOG35-55 sequence. At concentrations of 10 pM
(10
-11 M) to 1 uM (10
-6 M), the stimulatory activity of
GMCSF-MOG reflected a broad bell-shaped curve that
varied from 43 to 88 (x 10
3) cpm whereas MOG35-55
was substantially less potent but at high concentrations
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×1 0
3 cpm). A recombinant macaca IgV-MOG protein
which contained two differences (rat/macaca S42P and
K55R) did not stimulate this T cell line. GM-CSF alone
did not stimulate proliferative activity (data not shown).
GMCSF-MOG pre-treatment prevented a subsequent
phase of EAE
To assess whether GMCSF-MOG could prevent EAE,
the TTV was administered as a pre-treatment regimen
(2 nmole dose subcutaneously in saline) at 3, 2, and 1
w e e k sb e f o r ee n c e p h a l i t o g e n i cc h a l l e n g e( T a b l e1a n d
Figure 3). In experiments 1 and 2 combined, the TTV
pretreatment prevented EAE in 12 of 13 mice for an
incidence of 7.7%. That is, twelve mice had a maximal
score of zero (no disease) and one mouse exhibited
severe EAE (maximal score of 4.0). In contrast, mice
pretreated with MOG35-55 or saline exhibited an inci-
dence of 100% and 93.8% respectively (Table 1). In the
MOG-35-55 pretreated groups, 14 of 16 exhibited severe
EAE (≥ 4.0 maximal score) whereas 2 mice exhibited
mild EAE (scores of 1.0). In the saline-pretreated
g r o u p s ,1 5o f1 6m i c eh a ds c o r e so f4 . 0w h e r e a so n e
mouse did not exhibit EAE. Thus, the GMCSF-MOG
pretreatment reduced the mean cumulative score, mean
maximal score, and the mean number of days with
severe EAE. The GMCSF-MOG prevented the develop-
ment of EAE in a majority of mice over a prolonged
period of 40-50 days (Figure 3A, C). GMCSF-MOG also
prevented the weight loss associated with EAE whereas
mice pretreated with MOG35-55 or saline had a sus-
tained loss of body weight (Figure 3B, D). These data
Figure 1 The NAg domain of murine GMCSF-NAg TTV did not interfere with cytokine bioactivity. Designated concentrations (x-axis) of
murine GM-CSF, rat GM-CSF, murine GMCSF-MOG, or murine GMCSF-PLP were cultured with C57BL/6 bone marrow cells (100,000 cells per well)
(A) or FDC-P1 cells (10,000 cells per well) (B). Cultures were pulsed with 1 uCi of [
3H]thymidine (A) or MTS/PMS (B) during the last 24 hours of a
3-day culture. These data are representative of four experiments.
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C57BL/6 mouse model of EAE.
As previously shown for rat GMCSF-NAg TTV, the
murine GMCSF-MOG TTV required physical linkage of
GM-CSF and NAg domains for tolerogenic activity
(Table 2 and Figure 4). Mice pretreated with GMCSF-
MOG were largely protected from subsequent EAE.
Only 3 of 16 mice pretreated with the TTV showed
EAE, and the course was mild (Table 2 experiments 1
and 2 combined). Maximal scores for these mice were
2.0, 2.0, and 0.5. In contrast, mice pretreated with a
mixture of GM-CSF and NAg had severe paralytic EAE.
In this group, 15 of 16 mice had a maximal score of 4.0
whereas one mouse had a maximal score of 2.0. Mice
pre-treated with GM-CSF did not differ in severity or
time-course from saline-treated mice (Figure 4A, B)
(note that the GM-CSF treatment group was not
performed in experiment 2; Figure 4C, D). In this group,
all mice had maximal scores of 3.5 (2 mice) or 4.0 (6
mice). Mice pre-treated with MOG35-55 had a slightly
delayed onset but otherwise exhibited a full paralytic
course of EAE (14 mice had maximal scores of ≥ 3.5
whereas 2 mice had scores of 0.5 and 2.0). Mice pre-
treated with saline had severe EAE (14 of 16 had scores
ranging from 3.0 to 5.0 whereas the two additional mice
had scores of 2.0). Unlike the other pre-treatment
groups, GMCSF-MOG prevented the EAE-associated
loss of body weight (Figure 4B, D), and the covalent
linkage of GMCSF with MOG35-55 was required for
maintenance of normal body weight.
Mice successfully treated with GMCSF-MOG that had
a clinical score of 0 did not exhibit histological evidence
of EAE whereas EAE-afflicted control mice had abun-
dant focal lesions of the CNS. These CNS lesions were
Figure 2 The GM-CSF domain of murine GMCSF-MOG potentiated the antigenic recognition of MOG35-55 by rat T cells. (A) The rat T
cell clone RsL.11 or the rat 1E2 or 1B3 T cell hybrids were cultured with Lewis rat splenic APC and designated concentrations (x-axis) of the rat
GMCSF-(GP69-88) fusion protein or the GP69-88 synthetic peptide. Supernatants were collected after 24 hrs of culture and assayed for IL-2
production. (B) A rat MOG(35-55)-specific T cell line was cultured with rat splenic APC and designated concentrations of murine GMCSF-MOG,
the synthetic MOG35-55 peptide, or the IgV extracellular domain of rat or macaca MOG. Cultures were pulsed with 1 uCi of [
3H]thymidine during
the last 24 hours of a 3-day culture. These data are representative of four experiments.
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in white matter of the spinal cord (Figure 5). Overall,
pretreatment with the GMCSF-MOG reduced EAE inci-
dence, the cumulative score, the maximal disease score,
weight loss, and the mean number of days that mice
w e r ea f f l i c t e db ys e v e r eE A E .D u et ot h er e q u i r e m e n t
for linked cytokine and NAg domains, GMCSF-MOG
appeared to target the covalently-tethered NAg to APC
in vivo as part of the tolerogenic mechanism. Overall,
these data indicate that GMCSF-NAg TTV mediate
antigen-targeting in both mice (Table 2) and rats [15].
GMCSF-PLP pre-treatment prevented a subsequent phase
of EAE
Given that GMCSF-NAg TTV were able to inhibit both
monophasic (Lewis rats) and chronic progressive
(C57BL/6 mice) models of EAE, an important question
was whether GMCSF-NAg could inhibit relapsing-remit-
ting EAE. Thus, GMCSF-PLP TTV was tested for tol-
erogenic activity in SJL mice (Table 3 and Figure 6).
Mice were administered 2 nmoles GMCSF-PLP, 2
nmoles PLP139-151, or saline on days -21, -14, and -7
and then were challenged with 200 ug PLP139-151 in
Complete Freund’s Adjuvant (CFA) on day 0. One
TTV-treated mouse exhibited EAE (incidence of 1/8,
score of 1.0 for a total of 1 day) whereas mice pre-trea-
ted with either saline or PLP139-151 exhibited pro-
tracted, relapsing-remitting EAE. These data provide
evidence that GMCSF-NAg TTV were effective in a sec-
ond murine model of EAE.
GMCSF-PLP was also a more potent as an antigen
than the synthetic PLP139-151 peptide (Figure 7). The
potency enhancement attributed to the covalent attach-
ment with GM-CSF was approximately 10-fold and was
independent of whether APC were obtained from the
spleen (Figure 7A) or thymus (Figure 7B). GMCSF-
MOG was also more potent than MOG35-55 for stimu-
lation of a murine MOG-specific T cell line whereas
GM-CSF did not stimulate proliferation (Figure 7C).
The potency enhancement was evident over a wide con-
centration range and extended into the low picomolar
range as was evident when the data were re-plotted on a
logarithmic y-axis (Figure 7D). As noted previously (Fig-
ure 2), the same murine GMCSF-MOG TTV showed an
approximate 1000-fold potency enhancement when
tested in a rat T cell system.
GMCSF-MOG was a therapeutic that inhibited the effector
phase of an encephalitogenic attack
A central question was whether the GMCSF-MOG TTV
can be used as an intervention in chronic EAE (Table 4
and Figure 8). Treatment was started on day 13 when
the initial clinical signs of EAE first appeared in mice.
The incidence of EAE was 1 of 8 mice for each group
on day 13 (score was 1.0 for each mouse). Additional
treatments were administered on days 15, 17, and 20.
Table 1 GMCSF-MOG prevented a subsequent bout of EAE induced by challenge with MOG35-55 in CFA
Exp.
#
Pre-
treatment
a
Mean cum.
score
b
Median cum.
score
b
Mean
max.
score
b
Median max.
score
b
% mean initial
weight
b
Incidence
of EAE
c
Mean # days with
severe EAE
c
1 Saline 102.6 ± 48.9 115.5 3.5 ± 1.4 4.0 77.9% 7 of 8 18.3 ± 7.6
MOG 103.8 ± 16.6 106.3 4.0 ± 0.0 4.0 72.5% 8 of 8 18.3 ± 1.8
GMCSF-
MOG
18.3 ± 40.9 0.0 0.8 ± 1.8 0.0 93.6% 1 of 5 3.6 ± 8.0
TTV vs saline p = 0.05 p = 0.003 p = 0.015 p = 0.032 p = 0.002
TTV vs MOG p = 0.02 p = 0.001 p = 0.001 p = 0.007 p = 0.002
2 Saline 41.2 ± 19.4 44.8 4.0 ± 0.0 4.0 84.2% 8 of 8 10.1 ± 5.8
MOG 40.6 ± 24.3 45.8 3.4 ± 1.5 4.0 92.7% 8 of 8 8.9 ± 6.7
GMCSF-
MOG
0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 103.0% 0 of 8 0.0 ± 0.0
TTV vs saline p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.002
TTV vs MOG p < 0.001 p < 0.001 p = 0.021 p < 0.001 p = 0.007
a C57BL/6 mice were treated with 2 nmoles of GMCSF-MOG, 2 nmoles of MOG35-55, or saline. Injections were subcutaneous in saline and were given on days
-21, -14, and -7 (total combined dose of 6 nmoles) before active challenge on day 0 (200 ug of MOG35-55 in CFA with i.p. injections of Pertussis toxin on days 0
and 2). Table 1 and Figure 3 represent the same experiments. Experiments 1 and 2 correspond to the data shown in Figure 3A-B and 3C-D, respectively.
b Cumulative scores were calculated by summing daily scores for each mouse. Maximal scores were calculated as the most severe EAE score for each mouse.
Percent initial body weight was calculated as the minimum weight recorded between day 7 and the end of the experiment divided by the maximum weight
recorded from day 0 through day 7. For all tables, the mean cumulative and mean maximal scores included all mice within a group, even those not afflicted by
EAE. That is, the score of zero representing mice that did not exhibit EAE was included in the calculation of the respective mean values. Differences in median
values for cumulative and maximal scores were analyzed by nonparametric ANOVA based on ranked scores. Differences in mean values for percent initial body
weight and “number of days with severe EAE” were assessed by parametric ANOVA. ANOVA was interpreted with the Bonferroni post hoc test. Incidence of EAE
was analyzed pair-wise by Fisher’s Exact Test.
c Severe EAE was defined as hindlimb paresis or paralysis (clinical score of 3.0 or greater).
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EAE in a majority of mice whereas mice treated with
MOG35-55 progressed to severe EAE. Of the GMCSF-
MOG TTV-treated mice, 2 of 8 exhibited EAE, and one
had clinical signs before initiation of treatment. Only 1
of 8 mice had a brief episode of severe EAE (score of 2
for a total of 2 days). The main conclusion was that the
GMCSF-MOG TTV effectively stopped the progression
of EAE. The rank order for inhibition of EAE was:
GMCSF-MOG > MOG35-55 > saline. Compared to the
saline-treated group, mice treated with MOG35-55 also
had less severe EAE, although GMCSF-MOG had super-
ior inhibitory efficacy compared to MOG35-55. These
data indicate that GMCSF-MOG, and to a lesser extent,
MOG35-55, inhibited the effector phase of EAE.
GMCSF-MOG was also tested as a therapeutic agent
in an alternative model (Table 5 and Figure 9). EAE was
passively-induced by adoptive transfer of encephalito-
genic T cells, and then, after onset of clinical signs,
three treatments were administered on days 9, 11, and
14. Because all mice had EAE before the initiation of
treatment, the incidence of EAE in all groups was 100%.
Following partial recovery from the initial passive bout
of EAE, mice were actively challenged with MOG35-55
in CFA on day 42 but were not given any additional
treatment with TTV. The GMCSF-MOG TTV, when
administered on days 9, 11, and 14, blunted the initial
bout of passive EAE, inhibited residual disease, and atte-
nuated the subsequent bout of active EAE. Overall,
these data show that therapeutic administration of TTV
Figure 3 The murine GMCSF-MOG TTV induced tolerance and prevented a subsequent episode of EAE. C57BL/6 mice were treated with
2 nmoles of GMCSF-MOG, 2 nmoles of MOG35-55, or saline on days -21, -14, and -7 before active challenge on day 0 with 200 ug of MOG35-55
in CFA and two i.p. injections of Pertussis toxin on days 0 and 2. Table 1 and Figure 3 portray the same experiment. In experiment #1 (A-B), daily
clinical disease scores for mice treated with GMCSF-MOG were significantly different from those treated with MOG35-55 (days 16-34).
Comparison of “GMCSF-MOG versus saline” groups also revealed significant differences from days 15-19 and 24-28. In experiment #2 (C-D), daily
clinical scores for GMCSF-MOG treated mice were significantly different from mice treated with MOG35-55 (days 13-30) or saline (days 11-30).
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pronounced inhibitory effect on the subsequent active
induction of EAE as measured by both cumulative and
maximal disease scores. These data indicate that tolero-
genic activity can be initiated in peripheral lymphoid tis-
sues despite ongoing inflammation in the CNS.
Discussion
GM-CSF as a tolerogenic fusion partner
The purpose of this study was to assess whether a mur-
ine TTV comprised of mouse GM-CSF and encephalito-
genic epitopes from MOG or PLP effectively controlled
chronic forms of EAE in mice. A previous study showed
that a single-chain TTV comprised of rat GM-CSF and
the major encephalitogenic epitope of MBP was effective
for controlling the monophasic form of EAE in the
Lewis rat [15]. Chronic and monophasic models of EAE
however differ substantially in mechanism. Particularly,
monophasic forms of EAE may be self-limiting due to
robust regulatory responses that enable recovery and
prevent relapses. In contrast, chronic forms of EAE
appear to feature inefficient regulatory mechanisms that
cannot reverse CNS inflammation. To assess this
question, we derived murine GMCSF-MOG(35-55) and
GMCSF-PLP(139-151) TTV and tested these fusion pro-
teins in the C57BL/6 chronic progressive model and the
SJL relapsing-remitting model of EAE, respectively.
When administered as three injections before active
immunization, GMCSF-MOG prevented chronic pro-
gressive EAE in C57BL/6 mice (Tables 1, 2, Figures 3,
4), and GMCSF-PLP prevented relapsing-remitting EAE
in SJL mice (Table 3 Figure 6), respectively. Overall,
these data indicate that specific GMCSF-NAg TTV were
effective in three models of EAE, including both mouse
and rat species as well as monophasic, chronic progres-
sive, and relapsing remitting models of EAE.
Rat GMCSF-NAg TTV (Figure 2A), the murine
GMCSF-PLP (Figure 7A, B), and GMCSF-MOG (Figure
7C, D) exhibited enhanced antigen presentation com-
pared to the respective NAg. Due to the full cross-spe-
cies reactivity of GM-CSF, murine GMCSF-MOG was
targeted to both rat (Figure 2B) and murine APC (Fig-
ure 7C, D) to mediate enhanced antigen presentation to
rat and mouse MOG-specific T cells. These data reveal
that the NAg domain is efficiently targeted, processed,
and presented to T cell clones specific for the respective
Table 2 GMCSF-MOG required physically-linked cytokine and NAg domains for tolerance induction
Exp.
#
Treatment
a Mean cum.
score
Median cum.
score
Mean max.
score
Median max.
score
% mean initial
weight
Incidence of
EAE
b
Mean # days with
severe EAE
b
1 Saline 71.9 ± 24.2 63.3 4.0 ± 0.7 4.0 82.1% 8 of 8 13.8 ± 10.0
1 GM-CSF 68.3 ± 23.6 64.0 3.9 ± 0.2 4.0 82.0% 8 of 8 13.6 ± 10.9
1 MOG35-55 102.1 ± 13.3 103.0 4.0 ± 0.0 4.0 81.8% 8 of 8 26.3 ± 3.8
1 GM-CSF +
MOG
93.3 ± 19.5 90.5 4.3 ± 0.5 4.0 78.7% 8 of 8 23.1 ± 5.9
1 GMCSF-MOG 4.8 ± 13.0 0.0 0.3 ± 0.7 0.0 100.7% 2 of 8 0.0 ± 0.0
1 TTV vs Saline p = 0.001 p < 0.001 p < 0.001 p = 0.007 p = 0.005
1 TTV vs GM-
CSF
p = 0.004 p < 0.001 p < 0.001 p = 0.007 p = 0.030
1 TTV vs
MOG35-55
p < 0.001 p < 0.001 p < 0.001 p = 0.007 p < 0.001
1 TTV vs
“mixture”
p < 0.001 p < 0.001 p < 0.001 p = 0.007 p = 0.0002
2 Saline 74.1 ± 38.1 66.8 3.3 ± 0.9 3.5 89.5% 8 of 8 6.5 ± 8.8
2 MOG35-55 70.9 ± 44.5 81.5 3.2 ± 13 3.8 91.6% 8 of 8 7.6 ± 10.1
2 GM-CSF +
MOG
78.4 ± 36.3 93.5 3.8 ± 0.7 4.0 84.9% 8 of 8 7.7 ± 6.3
2 GMCSF-MOG 3.0 ± 8.5 0.0 0.3 ± 0.7 0.0 100.1% 1 of 8 0.0 ± 0.0
2 TTV vs Saline p = 0.001 p < 0.001 p = 0.005 p = 0.0014 p = 0.033
2 TTV vs
MOG35-55
p = 0.001 p < 0.001 p = 0.030 p = 0.0014 p = 0.017
2 TTV vs
“mixture”
p < 0.001 p < 0.001 p < 0.001 p = 0.0014 p = 0.004
a Mice were treated with GMCSF-MOG, a mixture of murine GM-CSF and MOG35-55, the MOG35-55 peptide, GM-CSF, or saline subcutaneously on days -21, -14,
and -7 (n = 8, all groups, 2 nanomoles per dose). Mice were then immunized on day 0 with 200 ug MOG35-55 in CFA plus Pertussis toxin (200 ng i.p.) on days 0
and 2. Table 2 and Figure 4 represent the same experiments. Data were analyzed as described for Table 1.
b Severe EAE was defined as hindlimb paresis or paralysis (clinical score of 3.0 or greater).
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age of the GM-CSF and NAg domains that was required
for antigen targeting and enhanced presentation of NAg
by DC was also required for tolerogenic activity in vivo.
In Lewis rats, physical linkage of the GM-CSF and NAg
domains was needed for prevention and therapy of EAE
[15]. To assess this question for murine TTV, we
focused on the C57BL/6 model of EAE. As shown in
Table 2 and Figure 4, tolerogenic activity of GMCSF-
MOG was entirely contingent upon the covalent linkage
of GM-CSF and MOG35-55 because administration of
the two agents as an equimolar mixture of separate
molecules did not suppress disease. Pre-treatment with
either GM-CSF alone or NAg alone also did not affect
EAE. The requirement for physical linkage of the GM-
CSF and NAg domains for tolerogenic activity in vivo
provided evidence that a mechanism of antigen targeting
was required for inhibition of EAE.
GMCSF-MOG also halted progression of EAE when
administration of the TTV was initiated at disease onset
(Table 4 Figure 8). Treatment was initiated when the
mice first began to show clinical signs on day 13.
Figure 4 Induction of MOG-specific tolerance required covalent linkage of the GM-CSF and MOG domains. C57BL/6 mice were treated
with GMCSF-MOG, a mixture of murine GM-CSF and MOG35-55, the MOG35-55 peptide, GM-CSF, or saline subcutaneously on days -21, -14, and
-7 (n = 8, all groups, 2 nanomoles per dose). Mice were then immunized on day 0 with 200 ug MOG35-55 in CFA plus Pertussis toxin (200 ng i.
p.) on days 0 and 2. Table 2 and Figure 4 represent the same experiments. In experiment #1 (A-B), daily clinical scores for mice treated with
GMCSF-MOG were significantly different from those treated with “GM-CSF + MOG35-55” (days 12-42), MOG35-55 (days 14-42), GM-CSF (days 12-
42), and saline (days 10-52). In experiment 2 (C-D), daily clinical scores for mice treated with GMCSF-MOG were significantly different from those
treated with “GM-CSF + MOG35-55” (days 14-52), MOG35-55 (days 16-52), and saline (days 13-52).
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Figure 5 GMCSF-MOG TTV prevented histological signs of EAE. Shown are representative histological sections from mice from Figure 4,
experiment 2. Mice from control groups that were afflicted with severe EAE had perivascular infiltrations of mononuclear cells typical of EAE in
the cervical (a) and lumbar (b, c) regions of the spinal cord. In contrast, GMCSF-MOG treated mice did not show inflammatory lesions in the
CNS, as portrayed by the cervical (d) and lumbar sections (e, f) of the spinal cord.
Table 3 GMCSF-PLP prevented a subsequent bout of EAE induced by challenge with PLP139-151 in CFA
Pre-
treatment
a
Mean cum.
score
b
Median cum.
score
b
Mean
max.
score
b
Median max.
score
b
% mean initial
weight
b
Incidence
of EAE
c
Mean # days with severe
EAE
b
Saline 43.1 ± 36.3 37.3 2.9 ± 1.5 3.5 87.1% 7 of 8 13.6 ± 12.8
PLP139-151 37.2 ± 35.4 31.0 2.5 ± 1.8 3.0 88.8% 6 of 8 12.4 ± 12.6
GMCSF-PLP 0.1 ± 0.4 0.0 0.1 ± 0.4 0.0 97.9% 1 of 8 0.0 ± 0.0
TTV vs saline p = 0.002 p = 0.002 p = 0.004 p = 0.010 p = 0.047
TTV vs PLP p = 0.011 p = 0.007 p = 0.016 p = 0.041 ns
a SJL mice were treated with 2 nmoles of GMCSF-PLP (n = 8 each group), 2 nmoles of PLP139-151, or saline. Injections were subcutaneous in saline and were
given on days -21, -14, and -7 (total combined dose of 6 nmoles) before active challenge on day 0 (200 ug of PLP139-151 in CFA). Table 3 and Figure 6
represent the same experiment. Data were analyzed as described for Table 1.
b Mice were scored daily for clinical signs of EAE through day 50.
c Incidence of EAE was the same as the incidence of severe EAE. Severe EAE was defined as ataxia through full hindlimb paresis or paralysis (clinical score of 2.0
or greater).
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Page 9 of 18Hence, treatment was initiated during early onset at a
time when effector T cells were first transitioning to the
CNS. Additional treatments were given on days 15, 17,
and 20. Administration of GMCSF-MOG at these time-
points blocked the progression of disease. In contrast,
mice treated with MOG35-55 or saline progressed to
paralytic disease, although mice treated with MOG35-55
had a less severe course than those treated with saline.
These data indicated that GMCSF-MOG inhibited
established effector mechanisms underlying progression
of EAE. GMCSF-MOG was also able to attenuate a
model of passive EAE that was subsequently boosted by
an active challenge (Table 5 Figure 9). In this case,
treatment with GMCSF-MOG was initiated when most
mice were already afflicted with EAE. GMCSF-MOG
accelerated recovery and blunted the subsequent active
induction of EAE. Thus, even during peak CNS
inflammation in a prevailing immunogenic environment,
GMCSF-MOG attenuated disease. Overall, these data
indicated that GMCSF-MOG is tolerogenic in both
quiescent, non-inflammatory environments as well as
activated, pro-inflammatory environments.
Targeting of NAg to DC is a potent means of tolerance
induction
Recombinant antibody-antigen fusion proteins specific
for DEC-205 (CD205) also targeted covalently tethered
foreign peptide antigen to DC for enhanced presentation
by a mechanism that resulted in antigen-specific toler-
ance [19,20]. When antigen was targeted to DC, trans-
genic T cells initially exhibited a burst of antigen-
specific proliferation, but the response collapsed and tol-
erance emerged. Similar antibody-antigen fusion pro-
t e i n sw e r ea l s ou s e dt op r e v e n tt h ei n d u c t i o no fE A E
Figure 6 The murine GMCSF-PLP TTV induced tolerance and prevented a subsequent episode of EAE.S J Lm i c ew e r et r e a t e dw i t h2
nmoles of GMCSF-PLP (n = 8 each group), 2 nmoles of PLP139-151, or saline on days -21, -14, and -7 before active challenge on day 0 (200 ug
of PLP139-151 in CFA). Table 3 and Figure 6 represent the same experiment. Daily clinical scores for mice treated with GMCSF-PLP(139-151) were
significantly different from those treated with saline (days 12-15, 18-22, 25-34).
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Page 10 of 18[21,22]. A recombinant anti-DEC205 antibody was
expressed that contained the MOG35-55 peptide as the
C-terminus. When administered 7 days before encepha-
litogenic challenge, this anti-DEC205-MOG fusion
protein blocked the subsequent development of EAE.
The anti-DEC205-MOG fusion protein did not cause
clonal deletion of MOG-specific T cells but rather eli-
cited clonal anergy in association with elevated CD5
Figure 7 The murine GMCSF-PLP and GMCSF-MOG TTV targeted NAg to APC for enhanced antigen presentation. A PLP139-151-specific
T cell line (A-B) or MOG35-55-specific T cell line (C-D) was cultured with irradiated SJL splenocytes (A), irradiated SJL thymocytes (B), or irradiated
C57BL/6 splenocytes (C-D) as a source of APC together with designated concentrations (x-axis) of GMCSF-NAg, antigen, GM-CSF, or PLP139-151.
C and D show the same data plotted on linear and logarithmic y-axes. Cultures were pulsed with [
3H]thymidine during the last 24 hrs of a 72 hr
culture. These data are representative of three experiments.
Table 4 The GMCSF-MOG TTV was a therapeutic treatment that blocked progression of actively-induced EAE
Treatment
a Mean cum.
score
Median cum.
score
Mean maximal
score
Median maximal
score
% mean initial
weight
Incidence of
EAE
b
Mean # days with
severe EAE
b
Saline 62.4 ± 17.3 69.0 3.6 ± 0.4 3.5 77.6% 8 of 8 18.6 ± 7.3
MOG35-55 32.4 ± 24.7 26.5 2.3 ± 1.3 2.5 88.9% 7 of 8 9.1 ± 9.0
GMCSF-MOG 3.4 ± 6.3 0.0 0.4 ± 0.7 0.0 88.9% 2 of 8 0.3 ± 0.7
TTV vs Saline p < 0.001 p < 0.001 p = 0.004 p = 0.007 p < 0.001
TTV vs
MOG35-55
p = 0.001 p = 0.004 ns p = 0.041 p = 0.007
MOG35-55 vs
saline
p = 0.024 p = 0.010 p = 0.004 ns p = 0.036
a Mice were immunized on day 0 with 200 ug MOG35-55 in CFA plus Pertussis toxin (200 ng i.p.) on days 0 and 2. Treatment was initiated when the first mice
began showing clinical signs. Mice were matched for clinical signs and were injected subcutaneously with saline or 2 nanomoles of the synthetic peptide
MOG35-55 or 2 nanomoles of the GMCSF-MOG TTV (in saline) on days 13, 15, 17, and 20. Mice were scored daily for clinical signs of EAE through day 38. Table 4
and Figure 8 represent the same experiment. Data were analyzed as described for Table 1.
b Severe EAE was defined as a clinical score of 2.0 or greater.
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Page 11 of 18Figure 8 GMCSF-MOG was an effective intervention that prevented progression of EAE.M i c ew e r ei m m u n i z e do nd a y0w i t h2 0 0u g
MOG35-55 in CFA plus Pertussis toxin (200 ng i.p.) on days 0 and 2. Treatment was initiated when the first mice began showing clinical signs.
Mice were matched for clinical signs and were injected subcutaneously with saline or 2 nanomoles of the synthetic peptide MOG35-55 or 2
nanomoles of the GMCSF-MOG TTV (in saline) on days 13, 15, 17, and 20. Table 4 and Figure 8 represent the same experiment. Daily clinical
scores for mice treated with GMCSF-MOG significantly differed from those treated with MOG35-55 (days 16-38) or saline (days 15-38). Daily
clinical scores for mice treated with MOG35-55 were significantly different from those treated with saline (days 18-22, 24, 32-36).
Table 5 The GMCSF-MOG TTV was an intervention that reversed an established course of chronic EAE
Treatment
a Mean cumulative
score
b
Median cumulative
score
b
Mean maximal
score
b
Median maximal
score
b
Incidence of
EAE
Mean # days with
severe EAE
Saline 47.9 ± 19.8 41.8 2.7 ± 0.5 3.0 6 of 6 20.0 ± 1.4
MOG35-55 27.6 ± 17.9 20.0 1.8 ± 0.8 2.0 6 of 6 13.8 ± 6.5
GMCSF-MOG 6.8 ± 4.6 4.5 0.8 ± 0.6 0.5 6 of 6 1.7 ± 2.7
TTV vs
MOG35-55
p = 0.008 p = 0.034 —— p = 0.051
TTV vs saline p < 0.001 p < 0.001 —— p = 0.001
a Passive EAE was induced in C57BL/6 mice by adoptive transfer of activated MOG35-55-specific T cells on day 0 and by injection of Pertussis toxin on days 0
and 2. Mice were matched for EAE severity on day 9 (mean maximal severity of 0.8 and an incidence of 100% for all groups), and were then treated with
GMCSF-MOG TTV or controls (subcutaneous in saline) on day 9 (4 nanomoles), day 11 (4 nanomoles), and day 14 (2 nanomoles). Mice were challenged with
MOG35-55 in CFA on day 42 and Pertussis toxin was injected i.p. on days 42 and 44 to elicit a second bout of active EAE. Table 5 and Figure 9 represent the
same data.
b The cumulative and maximal scores were assessed from days 12-70, and the incidence of severe EAE was assessed from days 15-70. An alternative clinical scale
was used for this experiment (0.5, tail involvement; 1.0, ataxia, 2.0 partial paralysis, 3.0, full paralysis), and mean number of days with severe EAE was assessed
from days 44-70 during the active challenge. Severe EAE was defined as a clinical score of 1.0 or greater.
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Page 12 of 18expression. Likewise, a fusion protein comprised of the
anti-DEC-205 mAb and the PLP139-151 epitope inhib-
ited the subsequent induction of EAE in SJL mice. Tol-
erance was associated with deletion and anergy in
pathogenic CD4
+ T cell subsets along with expansion of
regulatory T cell subsets. Overall, these studies provided
evidence that targeting of encephalitogenic NAg to DC
by use of anti-DEC205-NAg fusion proteins can lessen
susceptibility to EAE. These studies lend credence to
the hypothesis that efficient presentation of self antigens
by DC may be conducive for restoration of self tolerance
as a means to inhibit autoimmune demyelination.
Advantages of GM-CSF as a tolerogenic fusion partner for
NAg
GM-CSF is well-known as a pivotal cytokine that drives
differentiation of DC, including tolerogenic or regulatory
DC subsets. These APC subsets are important for induc-
tion and maintenance of self tolerance [23-34]. GM-CSF
directly promotes differentiation of DC subsets that in
turn facilitate Treg differentiation and antigen-specific
tolerance. Likewise, GM-CSF promotes differentiation of
myeloid derived suppressor cells that secrete anti-
inflammatory cytokines, mediators such as nitric oxide,
and enzymes such as IDO to downregulate T cell
Figure 9 GMCSF-MOG promoted tolerogenic activity despite ongoing inflammation in the CNS. Passive EAE was induced in C57BL/6 mice
by adoptive transfer of activated MOG35-55-specific T cells on day 0 and by injection of Pertussis toxin on days 0 and 2. Mice were matched for
EAE severity on day 9 (mean maximal severity of 0.8 and an incidence of 100% for all groups), and were then treated with GMCSF-MOG TTV or
controls (subcutaneous in saline) on day 9 (4 nanomoles), day 11 (4 nanomoles), and day 14 (2 nanomoles). Mice were challenged with MOG35-
55 in CFA on day 42 and Pertussis toxin was injected i.p. on days 42 and 44 to elicit a second bout of active EAE. Table 5 and Figure 9 represent
the same experiment. Daily clinical scores for mice treated with GMCSF-MOG were significantly different from those treated with “MOG35-55”
(days 54-57, 61-63, 65-70) or saline (days 28-58, 61-70). Thick arrows represent day 0 (adoptive transfer) and day 42 (active immunization). Thin
arrows represent days that mice were treated with GMCSF-MOG, MOG35-55, or saline.
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Page 13 of 18responses and confer tolerance [35-42]. Due to the
emerging recognition that GM-CSF and DC have
important regulatory dimensions, substantial emphasis
for development of GM-CSF-based cancer vaccines is
focused on breaching Treg-based regulatory networks
[43,44].
GM-CSF is now recognized as a potent regulatory
cytokine able to ameliorate disease in several mouse
models of autoimmunity. GM-CSF, when delivered
alone without a corresponding antigen, inhibited disease
in experimental autoimmune thyroiditis (EAT) [45-49],
experimental autoimmune myasthenia gravis (EAMG)
[50-52], and type I autoimmune diabetes (T1D) [53-55].
In CBA/J mice, treatment with GM-CSF before or after
immunization with thyroglobulin attenuated the severity
of EAT and reduced thyroglobulin-specific T cell auto-
immunity. Inhibition of EAT was contingent upon
enhanced IL-10 production and increased activities of
tolerogenic myeloid DC and CD4
+CD25
+ Foxp3
+ regula-
tory T cells. Likewise, GM-CSF treatment was effective
for both prevention and suppression of EAMG by a
mechanism associated with the reduction of autoreactive
T cell responses, lowered serum autoantibody produc-
tion, enhanced production of IL-10, enhanced suppres-
sive activity of myeloid DC, and expansion of Foxp3
+
Treg cells. GM-CSF treatment of NOD mice also inhib-
ited spontaneous development of autoimmune diabetes
by induction of regulatory CD11c
+ DC and Foxp3
+ T
cells. In accordance with the observation that GM-CSF
treatment inhibited T1D, a genetic deficiency of GM-
CSF enabled disease [56,57]. That is, T1D was evident
in aged C57BL/6 mice deficient in GM-CSF, and to a
greater extent, in aged mice deficient in both GM-CSF
and IL-3. These double-deficient mice exhibited a SLE-
like disease together with insulitis, loss of insulin-produ-
cing beta cells, and dysregulated blood glucose levels.
GM-CSF-deficient myeloid cells exhibited an impaired
phagocytosis of apoptotic cells [57,58]. Suboptimal pha-
gocytosis of apoptotic bodies may restrict an important
source of self peptides needed for diversification of the
Treg repertoire. Thus, defects in GM-CSF-mediated
phagocytosis and clearance of apoptotic cells may be
associated with insufficient development of the Treg
repertoire and development of autoimmune inflamma-
tory disease. GM-CSF treatment appears to reverse
these defects to restore self tolerance. Overall, these stu-
dies indicate that GM-CSF is pivotal for differentiation
of tolerogenic DC that in turn promote regulatory T cell
activities necessary for immune homeostasis.
The common link of these studies with our study of
GMCSF-NAg is that GM-CSF, either as an independent
regulatory cytokine or as a tolerogenic fusion partner,
had the essential activities that restored tolerance to
relevant self-antigens and thereby inhibited autoimmune
disease. The requirement for coupling of GM-CSF to
the relevant self-antigen in EAE (as opposed to EAT,
EAMG, and T1D) may reflect differences in underlying
pathogenic mechanisms, drug treatment regimens, and/
or bioavailability of the relevant antigens. One of the
main advantages of coupling self antigens to GMCSF is
that GMCSF would predictably target that antigen with
high efficiency to the regulatory APC subsets most
directly implicated in self tolerance, potentially including
a continuum of tolerogenic DC, myeloid derived sup-
pressor cells, and immature or semi-mature DC. Target-
ing self-antigen to these APC may represent a key
innovation toward achieving high-efficiency presentation
of self antigens by APC known to enhance Treg
responses, reverse autoimmune disease, and restore self-
tolerance.
Conclusions
The GM-CSF domain of GMCSF-NAg TTV serves as a
‘gateway’ to the immune system by catalyzing high-effi-
ciency uptake of the covalently-tethered NAg for pre-
sentation by myeloid APC. Overall, this study supports
the possibility that GM-CSF fusions with ‘self’ myelin
epitopes may represent a generalized approach for the
induction of tolerance to CNS myelin antigens.
Methods
Structure and purification of recombinant proteins
Expression systems for thr e em u r i n eG M - C S Fb a s e d
fusion proteins (GM-CSF, GMCSF-MOG, and GMCSF-
PLP) were derived for this study. Murine GM-CSF con-
tained the native signal sequence “M-A-W-L-Q-N-L-L-
F-L-G-I-V-V-Y-S-L-S” w i t han o n - n a t i v ea l a n i n ea tt h e
second position to accommodate a Kozak translation
initiation site. The C-terminus had an 8-histidine affinity
tag without an intervening linker. The GMCSF-MOG
protein was identical except that the MOG35-55 “M-E-
V-G-W-Y-R-S-P-F-S-R-V-V-H-L-Y-R-N-G-K” was
encoded between the native GM-CSF and the 8-histi-
dine C-terminus. The GMCSF-PLP protein contained
the PLP139-151 sequence “H-S-L-G-K-W-L-G-H-P-D-
K-F” rather than MOG35-55 and was otherwise identi-
cal. PCR products were assembled by overlap extension
PCR and were inserted into the pCEP4 expression vec-
tor (Invitrogen) for transient expression in human
embryonic kidney (HEK) 293 cells. Expression superna-
tants containing the recombinant proteins were concen-
trated by ultrafiltration and were purified by affinity
chromatography based upon binding to a single chain
(scFv) anti-6 his antibody immobilized on a chitin resin
[59,60]. After elution, the fusion proteins were subjected
to a final affinity chromatography step on Ni-NTA agar-
ose columns (Qiagen, Valencia, CA, USA). Proteins
were concentrated and diafiltrated in Amicon Ultra-15
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Page 14 of 18centrifugal filter devices. Protein quantity was assessed
by absorbance at 280 nm. Purity was assessed by SDS-
PAGE. GMCSF-GP(69-87), referred to as GMCSF-NAg
in [15], was a fusion of rat GM-CSF with the 69-87
encephalitogenic sequence of guinea pig (GP) myelin
basic protein “Y-G-S-L-P-Q-K-S-Q-R-S-Q-D-E-N-P-V-
V-H”. The sequence of the GP69-88 peptide was: Y-G-
S-L-P-Q-K-S-Q-R-S-Q-D-E-N-P-V-V-H-F. The C-term-
inal Phe residue is not part of the major encephalito-
genic epitope recognized by Lewis rat T cells [61,62].
Animals and reagents
C57BL/6 and SJL mice were housed at East Carolina
University Brody School of Medicine. Animal care and
use was performed in accordance with approved animal
use protocols and guidelines of the East Carolina Uni-
versity Institutional Animal Care and Use Committee.
Synthetic MOG35-55 and PLP139-151 peptides were
obtained from University of North Carolina Micropro-
tein Sequencing & Peptide Synthesis Facility (Chapel
Hill, NC).
Cell lines and culture conditions
Cell lines were cultured in complete RPMI medium
[10% heat-inactivated fetal bovine serum, 2 mM gluta-
mine, 100 ug/ml streptomycin, 100 U/ml penicillin
(Whittaker Bioproducts, Walkersville, MD), 50 uM 2-
ME (Fisher Scientific, Pittsburgh, PA)]. The rat MOG
(35-55)-specific T cell line was a primary, IL-2 depen-
dent line derived from Lewis rats sensitized with
MOG35-55 in Complete Freund’s Adjuvant (CFA). Mur-
ine T cell lines were derived from C57BL/6 and SJL
mice sensitized with 200 ug of MOG35-55 or PLP139-
151 in CFA, respectively. T cell lines were propagated in
complete RPMI supplemented with recombinant rat IL-
2 (0.4% v/v Sf9 supernatant) [63]. The 11B11 hybridoma
(ATCC HB-188), FDC-P1 (ATCC CRL-12103), and
CTLL (ATCC TIB-214) lines were obtained from the
American Type Culture Collection. 11B11 was a hybri-
doma that secreted a rat anti-mouse IL-4 monoclonal
antibody. FDC-P1 and CTLL lines were used as indica-
tor cells for measurement of GM-CSF and IL-2. The
FDC-P1 line was derived from DBA/2 bone marrow
cells, and the CTLL line was an IL-2-dependent murine
T cell line.
Bioassays
To measure proliferation, cultures were pulsed with 1
uCi of [
3H]thymidine (6.7 Ci/mmol, Perkin Elmer, Wal-
tham, MA, USA) during the last 24 hr of a 72 hr cul-
ture. Cultures were harvested onto filters by use of a
Tomtec Mach III harvester (Hamden, CT, USA). [
3H]
thymidine incorporation into DNA was measured by
use of a Wallac 1450 Microbeta Plus liquid scintillation
counter (Perkin Elmer, Waltham, MA). To measure IL-2
production, culture supernatants (100 ul) were trans-
ferred from the assay plate to a replicate plate, and
CTLL cells (10,000/well) in complete RPMI were added
to each well. Cultures were pulsed with MTS/PMS [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and
phenazine methosulfate (Promega, Madison, WI) during
the last 24 hr of a 72 hr culture, followed by measure-
ment of 490 nm absorbance. Error bars represented
standard deviations of triplicate or quadruplet sets of
wells. Bioassays portrayed in Figures 2 and 7 are repre-
sentative of at least three experiments.
Induction and treatment of EAE
CFA was prepared by mixing Incomplete Freund’s Adju-
vant with heat-killed Mycobacterium tuberculosis (4 mg/
ml) (BD Biosciences, Franklin Lakes, NJ). The CFA
adjuvant was mixed 1:1 with the designated dose of
antigen in saline and emulsified by sonication. Active
induction of EAE with synthetic peptides in CFA was
performed by subcutaneous injection across the back.
Each mouse received three separate injections (~ 0.033
ml per injection) for a total injection volume of 0.1 ml
per mouse. Passive EAE was induced by adoptive trans-
fer of activated encephalitogenic T cells. Donor mice
were actively sensitized with MOG35-55 in CFA. After
10-14 days, draining lymph nodes and splenocytes were
harvested from donor mice and were cultured with
MOG35-55, IL-12, and the 11B11 anti-IL-4 monoclonal
antibody. After 3 days of culture, activated T cells were
injected into recipients (0.5 ml total volume by intraper-
itoneal injection). In designated protocols, sequential
passive and active EAE was induced in the same mice.
The first bout of EAE was induced by adoptive transfer
of activated encephalitogenic T cells. After peak disease,
the mice showed varying degrees of recovery. To elicit a
second uniformly-intense second bout of EAE, mice
were actively challenged with MOG35-55 in CFA. For
passive and active induction of EAE, C57BL/6 mice
received an injection of 200 ng of Pertussis toxin (List
Biological Labs, Inc., Campbell, CA) in PBS i.p. on the
day of immunization and again 48 hours later. Fusion
proteins or controls were administered to mice anesthe-
tized by isoflurane (Abbott Laboratories, Chicago, IL,
USA). Fusion proteins, synthetic peptides, or combina-
tions were solubilized in saline and injected subcuta-
neously in 0.1 - 0.2 ml volumes. Injection sites showed
no signs of inflammation.
Assessment of Clinical EAE
EAE was scored by the following scale: 0, no disease;
0.5, partial paralysis of tail without ataxia; 1.0, flaccid
paralysis of tail or ataxia but not both; 2.0, flaccid
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Page 15 of 18paralysis of tail and ataxia or impaired righting reflex;
3.0, partial hind limb paralysis marked by inability to
walk upright but with ambulatory rhythm in both legs;
3.5, same as above but with full paralysis of one leg; 4.0,
full hindlimb paralysis; 5.0, total hindlimb paralysis with
forelimb involvement or moribund. A score of 5.0 was a
humane endpoint for euthanasia. In Table 5 an alterna-
tive scoring scale was used (see footnote) representing
the previous scale routinely used in the lab. Disease
measurements included incidence of EAE, mean and
median cumulative score, mean and median maximal
scores, percent weight loss, incidence of severe EAE,
mean number of days with severe EAE, and clinical
scores for each day. Cumulative scores were calculated
by summing daily scores for each mouse. Maximal
scores were calculated as the most severe EAE score for
each mouse, including all mice within a group. Mice
that had a score of zero (that did not exhibit EAE) were
included in the calculation of the mean maximal score.
Cumulative and maximal scores were analyzed by non-
parametric ANOVA based on ranked scores. “Percent
mean initial weight” and “number of days with severe
EAE” was analyzed by parametric ANOVA. The thresh-
old for severe EAE was based on the average maximal
severity for each experiment and was defined in each
table legend. ANOVA was assessed with a Bonferroni
post hoc test. “Incidence of EAE and incidence of severe
EAE” was analyzed pair-wise by Fisher’s Exact Test.
Histological assessment of EAE
After humane euthanasia, brain and spinal cord were
fixed in 4% paraformaldehyde. Tissues were dehydrated
in graded ethanol, cleared with citriSolv (Fisher Scienti-
fic, Pittsburgh, PA), and embedded in a 100% paraffin
block. Parasagittal (10 micron thick) sections were
mounted onto glass slides and stained with hematoxylin
and eosin. Sections were imaged with a spot insight
digital camera connected to an Olympus Bx51 micro-
scope at 20× magnification and were scored for perivas-
cular lesions of EAE.
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